© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
March 9th 2021
Charles Argoff, MD, describes the current state of the opioid crisis from a multifaceted point of view, as well as provide context for upcoming discussions.
Experts discuss opioid crisis complexities, such as the able to manage pain appropriately and the impact of social and structural determinates of health.
March 18th 2021
Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.
Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.
March 23rd 2021
Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.
Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regard to naloxone.
April 1st 2021
Experts weigh in on protocols, policies, and programs that influence patient safety and address when a conversation should ensue with patients about naloxone.
Joshua Lynch, DO, EMT-P, FAAEM, FACEP, shares ways to improve naloxone accessibility, and Theresa Mallick-Searle, MS, RN-BC, ANP-BC, discusses stigmatization.
April 6th 2021
Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.
Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.